2023 World Conference on Lung Cancer (Posters)-EP11.03. Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study

EP11.03. Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the clinical outcomes of immunotherapy with or without radiation in patients with advanced lung cancer. The study included 72 patients who received immunotherapy-containing regimens as their first-line treatment. <br /><br />The results showed that the addition of radiation therapy to immunotherapy may lead to longer progression-free survival (PFS) and overall survival (OS). At a median follow-up of 11.15 months, 54.17% of patients reached PFS endpoints and 26.39% reached OS endpoints. The median PFS was 10.61 months and the median OS was 13.18 months. <br /><br />The patients were divided into two groups: the radiation before resistance (RBR) group, which received radiation therapy before or during immunotherapy, and the non-radiation before resistance (NRBR) group, which did not receive radiation therapy. The median duration of immunotherapy was 10.54 months in the RBR group, compared to 8.44 months in the NRBR group. <br /><br />In terms of disease progression, 46.15% of patients in the RBR group experienced disease progression or death, compared to 60.87% in the NRBR group. The median PFS was 13.60 months in the RBR group and 10.33 months in the NRBR group. <br /><br />The median OS was 18.64 months in the RBR group, which was higher than the median OS of 13.84 months in the NRBR group. However, these differences were not statistically significant. <br /><br />Overall, the study suggests that the addition of radiation therapy to immunotherapy may extend the duration of immunotherapy and potentially lead to longer PFS and OS in advanced lung cancer patients. Only two patients in the NRBR group experienced grade 3 side effects. <br /><br />Further research is needed to confirm these findings and determine the optimal combination and sequence of immunotherapy and radiation therapy in the treatment of advanced lung cancer.

Asset Subtitle

Jiafeng Liang

Meta Tag

Speaker Jiafeng Liang

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

clinical outcomes

immunotherapy

radiation

advanced lung cancer

progression-free survival

overall survival

first-line treatment

disease progression

side effects